Filing Flows › Comparisons › BDSX vs XGN
Biodesix vs Exagen: BDSX and XGN compared
Biodesix is the larger company: $24.0M of revenue in its latest quarter (Q3 2026) against $19.9M for Exagen (Q2 2026). Exagen is growing faster (+16% against +10% a year earlier). Exagen is more profitable, with an operating margin of -8.6% against -25.4%.
Where the money goes: BDSX and XGN
Biodesix (BDSX) · Q3 2026
Biodesix, Q3 2026: revenue $24.0M (+10% year over year), operating margin -25.4%, net loss $8.0M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Exagen (XGN) · Q2 2026
Exagen, Q2 2026: revenue $19.9M (+16% year over year), operating margin -8.6%, net loss $3.2M, operating cash flow $4.0M. The chart follows the revenue to costs, profit and cash.
| Biodesix (BDSX) | Exagen (XGN) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $24.0M | $19.9M |
| Revenue growth, Y/Y | +10% | +16% |
| Operating margin | -25.4% | -8.6% |
| Net earnings | −$8.0M | −$3.2M |
| Net margin | -33.4% | -16.0% |
| Operating cash flow | −$7.2M | $4.0M |
| Free cash flow | — | $3.4M |
Where the revenue comes from
Biodesix
- Diagnostic Tests: $23.1M (96%)
- Development Services: $986K (4%)
Questions
Which is bigger, Biodesix or Exagen?
Biodesix is the larger company: $24.0M of revenue in its latest quarter (Q3 2026) against $19.9M for Exagen (Q2 2026).
Is Biodesix or Exagen growing faster?
Exagen is growing faster (+16% against +10% a year earlier).
Which is more profitable, Biodesix or Exagen?
Exagen is more profitable, with an operating margin of -8.6% against -25.4%.
More: Biodesix earnings · how Biodesix makes money · Exagen earnings · how Exagen makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 4, 2026). Fiscal quarters can end on different dates. Not investment advice.